Assembly Biosciences, Inc. reported progress in its clinical development of antiviral candidates, with data from multiple programs expected in 2025. Specifically, interim Phase 1b data for long-acting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback